Trial · NCT00974376
Gabapentin Treatment of Cannabis Dependence
NCT00974376, Phase 2, Completed, The Scripps Research Institute; results first posted 2017-06-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Gabapentin Treatment of Cannabis Dependence. Trials, record NCT00974376. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00974376
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Gabapentin Treatment of Cannabis Dependence
- NCT number
- NCT00974376
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 150 participants, actual
- Lead sponsor
- The Scripps Research Institute
- Conditions
- Cannabis Dependence, Cannabis Withdrawal, Cognitive Deficits
- Interventions
- gabapentin 1200mg/day, Placebo, Manual-guided behavioral counseling
- First posted
- 2009-09-10
- Last updated
- 2017-06-06
- Results first posted
- 2017-06-06
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Negative Urinary Drug Screens (UDS) for Cannabis at 12 Weeks Following Administration of Gabapentin or Placebo During the Double Blind Period | 12 weeks | Express Results Integrated Multi-Drug Screen Cups were used to obtain a semi-quantitative urine drug screen for delta-9-THC. Submitted UDS would yield a positive result when the concentration of THC-COOH in urine exceeded 50 ng/mL. Specimens were collected weekly. Two analytical approaches were used: one where any missed UDS test was assumed positive (i.e intent-to-treat (ITT)) and another where missed UDS were considered missing at random (MAR). |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Negative Urinary Drug Screens (UDS) for Cannabis at 12 Weeks Following Administration of Gabapentin or Placebo During the Double Blind Period | 12 weeks | Two participants in the gabapentin group and one in the placebo group were lost to follow up after randomization and did not submit any UDS for testing while on study. Two participants in the placebo group withdrew from the study at the week 1 visit, and thus did not submit any UDS for testing while on study. | percentage of negative UDS | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Negative Urinary Drug Screens (UDS) for Cannabis at 12 Weeks Following Administration of Gabapentin or Placebo During the Double Blind Period | Gabapentin 1200mg/Day | % Negative UDS ITT | 11.22 | Standard Deviation 21.77 | percentage of negative UDS |
| Percentage of Negative Urinary Drug Screens (UDS) for Cannabis at 12 Weeks Following Administration of Gabapentin or Placebo During the Double Blind Period | Placebo | % Negative UDS ITT | 8.00 | Standard Deviation 19.83 | percentage of negative UDS |
| Percentage of Negative Urinary Drug Screens (UDS) for Cannabis at 12 Weeks Following Administration of Gabapentin or Placebo During the Double Blind Period | Gabapentin 1200mg/Day | % Negative UDS Observed | 12.48 | Standard Deviation 23.82 | percentage of negative UDS |
| Percentage of Negative Urinary Drug Screens (UDS) for Cannabis at 12 Weeks Following Administration of Gabapentin or Placebo During the Double Blind Period | Placebo | % Negative UDS Observed | 9.93 | Standard Deviation 24.03 | percentage of negative UDS |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Gabapentin 1200mg/Day | 75 | |
| Overall Study | STARTED | Placebo | 75 | |
| Overall Study | COMPLETED | Gabapentin 1200mg/Day | 41 | |
| Overall Study | COMPLETED | Placebo | 42 | |
| Overall Study | NOT COMPLETED | Gabapentin 1200mg/Day | 34 | |
| Overall Study | NOT COMPLETED | Placebo | 33 |
Source ClinicalTrials.gov
Adverse events32
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | Gabapentin 1200mg/Day | 5 | 75 | |
| other | Diarrhoea | Gastrointestinal disorders | Placebo | 8 | 75 | |
| other | Dyspepsia | Gastrointestinal disorders | Gabapentin 1200mg/Day | 1 | 75 | |
| other | Dyspepsia | Gastrointestinal disorders | Placebo | 4 | 75 | |
| other | Nausea | Gastrointestinal disorders | Gabapentin 1200mg/Day | 8 | 75 | |
| other | Nausea | Gastrointestinal disorders | Placebo | 8 | 75 | |
| other | Vomiting | Gastrointestinal disorders | Gabapentin 1200mg/Day | 4 | 75 | |
| other | Vomiting | Gastrointestinal disorders | Placebo | 2 | 75 | |
| other | Fatigue | General disorders | Gabapentin 1200mg/Day | 10 | 75 | |
| other | Fatigue | General disorders | Placebo | 3 | 75 |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Gabapentin 1200mg/Day | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Gabapentin 1200mg/Day | 40 | 75 |
| Total, other adverse events | Placebo | 50 | 75 |
| Total, serious adverse events | Gabapentin 1200mg/Day | 0 | 150 |
| Total, serious adverse events | Placebo | 1 | 150 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01DA026758 | Gabapentin Treatment of Cannabis Dependence | MASON, BARBARA J | SCRIPPS RESEARCH INSTITUTE, THE | NATIONAL INSTITUTE ON DRUG ABUSE | 2009 to 2013 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Gabapentin 1200mg/Day vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00974376
GET https://conductscience.org/api/trials/v1/NCT00974376/events?page=2